| Entry |
|
|---|
| Symbol |
IFNAR1, AVP, IFN-alpha-REC, IFNAR, IFNBR, IFRC
|
|---|
| Name |
(RefSeq) interferon alpha and beta receptor subunit 1
|
|---|
| KO |
|
|---|
| Organism |
|
|---|
| Pathway |
| hsa04060 | Cytokine-cytokine receptor interaction |
| hsa04620 | Toll-like receptor signaling pathway |
| hsa04621 | NOD-like receptor signaling pathway |
| hsa04650 | Natural killer cell mediated cytotoxicity |
| hsa05167 | Kaposi sarcoma-associated herpesvirus infection |
| hsa05168 | Herpes simplex virus 1 infection |
|
|---|
| Network |
nt06119 JAK-STAT signaling (viruses) nt06122 IFN signaling (viruses) nt06160 Human T-cell leukemia virus 1 (HTLV-1) nt06162 Hepatitis B virus (HBV) nt06163 Hepatitis C virus (HCV) nt06164 Kaposi sarcoma-associated herpesvirus (KSHV) nt06165 Epstein-Barr virus (EBV) nt06166 Human papillomavirus (HPV) nt06168 Herpes simplex virus 1 (HSV-1) nt06169 Measles virus (MV) nt06170 Influenza A virus (IAV) nt06171 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nt06219 JAK-STAT signaling nt06222 IFN signaling nt06263 Hepatocellular carcinoma nt06266 Non-small cell lung cancer nt06276 Chronic myeloid leukemia |
|---|
| Element |
| N00053 | Cytokine-Jak-STAT signaling pathway |
| N00150 | Type I IFN signaling pathway |
| N00471 | EBV LMP2A/2B to IFN signaling pathway |
|
|---|
| Drug target |
| Interferon alfa natural: | D03305<JP> |
| Interferon alfa-2b: | D02745<US> |
| Interferon beta natural: | D03304<JP> |
| Interferon beta-1a: | D04554<JP/US> |
| Interferon beta-1b: | D00746<JP/US> |
| Peginterferon alfa-2a: | D02747<JP/US> |
| Peginterferon alfa-2b: | D02748<JP/US> |
| Peginterferon beta-1a: | D10483<US> |
| Ropeginterferon alfa-2b: | D11027 |
|
|---|
| Brite |
KEGG Orthology (KO) [BR:hsa00001]
09130 Environmental Information Processing
09132 Signal transduction
04630 JAK-STAT signaling pathway
3454 (IFNAR1)
04151 PI3K-Akt signaling pathway
3454 (IFNAR1)
09133 Signaling molecules and interaction
04060 Cytokine-cytokine receptor interaction
3454 (IFNAR1)
09140 Cellular Processes
09143 Cell growth and death
04217 Necroptosis
3454 (IFNAR1)
09150 Organismal Systems
09151 Immune system
04620 Toll-like receptor signaling pathway
3454 (IFNAR1)
04621 NOD-like receptor signaling pathway
3454 (IFNAR1)
04650 Natural killer cell mediated cytotoxicity
3454 (IFNAR1)
09158 Development and regeneration
04380 Osteoclast differentiation
3454 (IFNAR1)
09160 Human Diseases
09161 Cancer: overview
05200 Pathways in cancer
3454 (IFNAR1)
09172 Infectious disease: viral
05161 Hepatitis B
3454 (IFNAR1)
05160 Hepatitis C
3454 (IFNAR1)
05171 Coronavirus disease - COVID-19
3454 (IFNAR1)
05164 Influenza A
3454 (IFNAR1)
05162 Measles
3454 (IFNAR1)
05168 Herpes simplex virus 1 infection
3454 (IFNAR1)
05167 Kaposi sarcoma-associated herpesvirus infection
3454 (IFNAR1)
05169 Epstein-Barr virus infection
3454 (IFNAR1)
05165 Human papillomavirus infection
3454 (IFNAR1)
09180 Brite Hierarchies
09183 Protein families: signaling and cellular processes
04050 Cytokine receptors [BR:hsa04050]
3454 (IFNAR1)
Cytokine receptors [BR:hsa04050]
Interleukin receptor families
IFN receptor family
3454 (IFNAR1)
|
|---|
| SSDB |
|
|---|
| Motif |
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| Structure |
PDB: |
|---|
| Position |
21q22.11
|
|---|
| AA seq |
557 aa
MMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT
FSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF
TPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI
ENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ
NQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK
GIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP
VIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV
FSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE
YFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN
EDESESKTSEELQQDFV |
|---|
| NT seq |
1674 nt +upstreamnt +downstreamnt
atgatggtcgtcctcctgggcgcgacgaccctagtgctcgtcgccgtggcgccatgggtg
ttgtccgcagccgcaggtggaaaaaatctaaaatctcctcaaaaagtagaggtcgacatc
atagatgacaactttatcctgaggtggaacaggagcgatgagtctgtcgggaatgtgact
ttttcattcgattatcaaaaaactgggatggataattggataaaattgtctgggtgtcag
aatattactagtaccaaatgcaacttttcttcactcaagctgaatgtttatgaagaaatt
aaattgcgtataagagcagaaaaagaaaacacttcttcatggtatgaggttgactcattt
acaccatttcgcaaagctcagattggtcctccagaagtacatttagaagctgaagataag
gcaatagtgatacacatctctcctggaacaaaagatagtgttatgtgggctttggatggt
ttaagctttacatatagcttagttatctggaaaaactcttcaggtgtagaagaaaggatt
gaaaatatttattccagacataaaatttataaactctcaccagagactacttattgtcta
aaagttaaagcagcactacttacgtcatggaaaattggtgtctatagtccagtacattgt
ataaagaccacagttgaaaatgaactacctccaccagaaaatatagaagtcagtgtccaa
aatcagaactatgttcttaaatgggattatacatatgcaaacatgacctttcaagttcag
tggctccacgcctttttaaaaaggaatcctggaaaccatttgtataaatggaaacaaata
cctgactgtgaaaatgtcaaaactacccagtgtgtctttcctcaaaacgttttccaaaaa
ggaatttaccttctccgcgtacaagcatctgatggaaataacacatctttttggtctgaa
gagataaagtttgatactgaaatacaagctttcctacttcctccagtctttaacattaga
tcccttagtgattcattccatatctatatcggtgctccaaaacagtctggaaacacgcct
gtgatccaggattatccactgatttatgaaattattttttgggaaaacacttcaaatgct
gagagaaaaattatcgagaaaaaaactgatgttacagttcctaatttgaaaccactgact
gtatattgtgtgaaagccagagcacacaccatggatgaaaagctgaataaaagcagtgtt
tttagtgacgctgtatgtgagaaaacaaaaccaggaaatacctctaaaatttggcttata
gttggaatttgtattgcattatttgctctcccgtttgtcatttatgctgcgaaagtcttc
ttgagatgcatcaattatgtcttctttccatcacttaaaccttcttccagtatagatgag
tatttctctgaacagccattgaagaatcttctgctttcaacttctgaggaacaaatcgaa
aaatgtttcataattgaaaatataagcacaattgctacagtagaagaaactaatcaaact
gatgaagatcataaaaaatacagttcccaaactagccaagattcaggaaattattctaat
gaagatgaaagcgaaagtaaaacaagtgaagaactacagcaggactttgtatga |
|---|
